Replies to post #163142 on Biotech Values

[DewDiligence]

According to Bloomberg, Celltrion has priced Remsima “at least 30%” below the typical European price of Remicade (http://www.bloomberg.com/news/2013-06-28/first-copy-of-j-j-s-6-billion-remicade-wins-ema-backing.html ).